Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company
focused on the development and commercialization of drugs for the
treatment of metabolic and endocrine diseases in niche markets with
unmet medical needs, today announced its financial results for the
three- and twelve-month periods ended December 31, 2005. -0- *T
Twelve- Twelve- Months Months Ended Ended Dec. 31, Dec. 31, $000's
(except EPS) Q4 2005 Q4 2004 2005 2004
--------------------------------------------- Revenues 24 23 131
137 Net loss (12,885) (5,837) (40,929) (27,203) Net cash used in
operations 6,209 6,452 27,765 24,901 Earnings per share (0.27)
(0.14) (0.84) (0.69)
---------------------------------------------------------------------
*T Discussion of Revenue and Expense Items Revenues for the three
months ended December 31, 2005 were $24,000 as compared to $23,000
for the same period in 2004, and $131,000 for the twelve months of
2005 as compared to $137,000 for the same period in 2004. The net
loss for the fourth quarter ended December 31, 2005 was $12.9
million or $0.27 per share, as compared to a net loss of $5.8
million or $0.14 per share for the corresponding quarter of 2004.
The net loss for the twelve months ended December 31, 2005 was
$40.9 million or $0.84 per share as compared to $27.2 million or
$0.69 per share for the full year of 2004. The $7.0 million
increase in the net loss for the fourth quarter of 2005, as
compared to the same quarter of 2004, was due to the combination of
a $6.0 million increase in interest expense, a $0.6 million rise in
research and development expenses and a $0.6 million increase in
general and administrative expenses, offset by a rise in investment
income of $0.2 million,. The $6.0 million rise in interest expense
resulted from the March 2005 convertible debt financing and
consisted of two components: $5.8 million of non cash expense
arising from the accounting treatment of the March 2005 convertible
debt financing, which requires that the amortization of the debt
discount and deferred offering costs of the financing be
accelerated as investors convert the debt into shares, and $0.2
million arising from actual interest paid on the notes. The higher
research and development expense was due to increased litigation
costs in support of our patent position, while the $0.6 million
rise in general and administrative expenses was due mainly to
increased external service costs in support of our business. The
increased investment income results from the Company having a
higher cash balance than the corresponding period of 2004. The net
loss for the twelve months ended December 31, 2005 was $13.7
million higher than the corresponding period for 2004 due to
increases of $14.2 million in interest expense and $1.5 million in
general and administration expenses, which were partially offset by
a reduction of $1.5 million in research and development expenses
and a rise in investment income of $0.5 million. The increase in
interest expense was due to the March 2005 financing and consisted
of $13.1 million of non cash expense relating to the accelerated
amortization of the deferred discount and offering costs, and $1.1
of actual interest paid on the notes. The reduction in research and
development expenses was principally due to lower development and
manufacturing costs for IPLEX(TM), which were partially offset by
increased litigation costs in support of our patent position, while
the higher general and administrative expenses were due to
increased costs associated with financing activities and additional
external service costs in support of our business. The rise in
interest income was due to the higher cash balance on hand. As of
December 31, 2005, the Company had total cash and cash equivalents
of $18.8 million which represents an increase of $9.6 million from
December 31, 2004. This increase was mainly due to the generation
of $37.4 million from financing activities, offset by the use of
$27.8 million in support of our business operations. The $37.4
million of cash from financing activities was generated from a
combination of $32.6 million in net proceeds from the March 2005
convertible debt offering, $4.6 million from the exercise of
warrants and $0.2 million from a reduction in a restricted letter
of credit. Between January 1, 2006 and February 28, 2006, the
Company received additional cash of $8.2 million from the exercise
of warrants. As a result of these conversions in the first two
months of 2006, the following shares, warrants and convertible debt
were outstanding as of February 28, 2006: -- 76.8 million total
shares -- $6.0 million in convertible debt from the March 2005
financing, convertible at $1.295 -- 6.2 million warrants from the
March 2005 financing convertible at $1.36 -- 2.3 million warrants
from the November 2004 financing convertible at $1.71, and -- 1.5
million warrants from the July 2003 financing convertible at $4.10
Conference Call The Company will host a conference call on
Thursday, March 2; at 4:30 p.m. Eastern Time to discuss operating
results for fiscal year 2005 and provide a business update.
Interested investors can listen to the call over the internet from
Insmed's investor relations website at www.insmed.com or by dialing
(800) 289-0529 (domestic) or 913-981-5523 (international). A
telephonic replay of the call will be available for one week at
888-203-1112 (domestic) or 719-457-0820 (international), passcode:
4436753. A web replay of the call will be available through our
corporate website, in the investor relations segment, beginning at
6:00 p.m. About Insmed Incorporated Insmed Incorporated is a
biopharmaceutical company focused on the discovery, development and
commercialization of drug products for the treatment of metabolic
diseases and endocrine disorders with unmet medical needs. For
further information about Insmed and IPLEX(TM) (mecasermin
rinfabate(rDNA origin) injection), our FDA-approved drug for the
treatment of growth failure in children with severe primary IGF-1
deficiency or with growth hormone deletion who have developed
neutralizing antibodies to growth hormone, please visit the
company's corporate website at www.insmed.com. Statements included
within this press release, which are not historical in nature, may
constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Although Insmed believes that such statements are based on
reasonable assumptions within the bounds of its knowledge of its
business and operations, the forward-looking statements are neither
promises nor guarantees and various factors may cause its actual
results to differ materially from its expectations. Forward-looking
statements all statements regarding expected financial position,
results of operations, cash flows, dividends, financing plans,
business strategies, operating efficiencies or synergies, budgets,
capital and other expenditures, competitive positions, commercial
acceptance of IPLEX(TM), growth opportunities for approved or
proposed products, plans and objectives of management, demand for
new pharmaceutical products, market trends in the pharmaceutical
business, inflation and various economic and business trends. Such
forward-looking statements are subject to numerous risks and
uncertainties, including risks that we may not successfully launch
IPLEX(TM), our product candidates may fail in clinical trials or
may not be successfully marketed, we may lack financial resources
to complete development of product candidates, we may be unable to
raise additional financing necessary to continue current
operations, we may not be able to sufficiently expand the
manufacturing capacity of our leased manufacturing facility in
Boulder, Colorado, and utilize that facility to manufacture our
approved product, IPLEX(TM), and other product candidates,
competing products may be more successful, we may have a negative
outcome of our current litigation with third parties regarding our
patent rights, demand for new pharmaceutical products may decrease
and the biopharmaceutical industry may experience negative market
trends. For further information with respect to factors that could
cause actual results to differ from expectations, reference is made
to reports filed by Insmed with the Securities and Exchange
Commission under the Securities Exchange Act of 1934, as amended.
The forward-looking statements made in this release are made only
as of the date hereof and Insmed disclaims any intention or
responsibility for updating predictions or financial guidance
contained in this release. -0- *T INSMED INCORPORATED Condensed
Consolidated Balance Sheets (in thousands, except share and per
share data) Dec. 31, Dec. 31, 2005 2004 --------- --------- Assets
Current assets: Cash and cash equivalents $18,835 $ 9,222
Restricted cash 285 285 Other current assets 83 174 ---------
--------- Total current assets 19,203 9,681 Long-term assets:
Restricted cash - long term 3,118 3,303 Deferred financing costs,
net 532 - Property and equipment, net 17 27 --------- ---------
Total long-term assets 3,667 3,330 Total assets $22,870 $13,011
========= ========= Liabilities and stockholders' equity Current
liabilities: Accounts payable $ 968 $ 2,621 Accrued project costs
& Other 1,990 884 Payroll liabilities 1,574 1,183 Interest
payable 52 - Restructuring reserve 286 360 --------- ---------
Total current liabilities 4,870 5,048 Long-term liabilities:
Convertible debt 11,438 - Debt discount (5,001) - ---------
--------- Net convertible debt 6,437 - Asset retirement obligation
1,034 443 Restructuring reserve-long-term portion - 285 ---------
--------- Total liabilities 12,341 5,776 --------- ---------
Stockholders' equity: Common stock; $.01 par value; authorized
share 500,000,000; issued and outstanding shares, 66,525,792 in
2005 and 44,893,496 in 2004 665 449 Additional capital 264,522
220,515 Accumulated deficit (254,658) (213,729) --------- ---------
Net stockholders' equity 10,529 7,235 --------- --------- Total
liabilities and stockholders' equity $22,870 $13,011 =========
========= INSMED INCORPORATED Condensed Consolidated Statements of
Operations (in thousands, except per share data - unaudited) Twelve
Months Ended Dec. 31, -------------------- 2005 2004
-------------------- Revenues $ 131 $ 137 Operating expenses:
Research and development 21,835 23,260 General and administrative
5,730 4,242 -------------------- Total operating expenses 27,565
27,502 -------------------- Operating loss (27,434) (27,365)
Interest income 752 222 Interest expense (14,247) (60)
-------------------- Net loss $(40,929) $(27,203)
==================== Basic and diluted net loss per share $ (0.84)
$ (0.69) ==================== Shares used in computing basic and
diluted net loss per share 48,742 39,160 ====================
INSMED INCORPORATED Consolidated Statements of Cash Flows (in
thousands - unaudited) Twelve Months Ended Dec. 31, 2005 2004
--------- --------- Operating activities Net loss $(40,929)
$(27,203) Adjustments to reconcile net loss to net cash used in
operating activities: Depreciation and amortization 12,897 34
Non-cash stock acceleration 15 - Stock options issued for services
33 33 Changes in operating assets and liabilities: Other assets 91
51 Accounts payable (1,653) 1,961 Accrued project costs 1,106 (863)
Payroll liabilities 391 978 Restructuring reserve (359) (335) Asset
retirement obligation 591 443 Interest payable 52 - ---------
--------- Net cash used in operating activities (27,765) (24,901)
--------- --------- Financing activities Proceeds from issuance of
convertible debt with detachable stock warrants 35,000 - Proceeds
from issuance of common stock 4,621 8,185 Costs incurred in
conjunction with issuance of debt (2,428) - Cash restricted to
restricted letters of credit 185 (3,588) --------- --------- Net
cash provided by (used in) financing activities 37,378 4,597
--------- --------- Increase (decrease) in cash and cash
equivalents 9,613 (20,304) Cash and cash equivalents at beginning
of period 9,222 29,526 --------- --------- Cash and cash
equivalents at end of period $18,835 $ 9,222 ========= =========
Supplemental information Cash paid for interest 1,104 - *T
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024